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Aim: Atrial ﬁbrillation (AF) can be successfully treated with interventional methods of
catheter or surgical ablation. New surgical minimally invasive methods have been created
for patients with a stand-alone form of AF.
Methods and results: In this article, we describe our eight years experiences with a thoraco-
scopic epicardial off-pump ablation. We narrate the methodology, indications and also
summarize our outcomes.
Conclusions: AF can be safely and successfully treated through a minimally invasive surgical
approach. Results can be improved with usage of bipolar radiofrequency energy and close
collaboration with electrophysiologists.
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Atrial ﬁbrillation (AF) represents the most common sus-
tained cardiac arrhythmia with a prevalence of nearly 2%
in general population [1]. It increases with age and the
number of patients suffering from AF in Europe is expected
to double within next 10 years. Presence of any type of AF is
associated with two-fold raise of mortality, increased risk of
cerebrovascular thromboembolic events, increased rate of
cardiac-related hospitalizations and also a deteriorative
quality of life [2]. Because of its serious social and ﬁnancial
impact, AF is sometimes called an epidemic of the 21st
century.
Effective treatment of AF still remains an opened problem.
Pharmacological methods with amiodarone as the drug of
ﬁrst choice have a limited efﬁcacy with signiﬁcant reccurence
rates and potential serious side effects. An important
improvement in the ﬁeld of antithrombotics present the
group of novel oral anticoagulants (NOACs) that have been
widely accepted as an equally effective alternative to warfarin
[3]. The group of interventional (catheter and surgical)
methods of AF treatment presents a dynamically evolving
and so far the most effective method of sinus rhythm (SR)
restoration nowadays.
Since the landmark article published by Haissaguerre in
1998 [4], the percutaneous catheter ablation (CA) became an
effective method of paroxysmal AF treatment and currently is
recommended for paroxysmal AF patients with symptomatic
recurrences despite optimal medical therapy with a class I/A
indication [4]. An electric isolation of pulmonary veins (PV) is a
key component of procedures for paroxysmal AF treatment.
Patophysiology of non-paroxysmal AF is much more complex.
Therefore, the treatment of persistent and long-standing
persistent AF with methods of CA is more complicated and
the long-term success rate of these procedures is currently
limited [5].
In 1987, an introduction of the MAZE procedure by Dr. Cox
has started an expansion and evolution of surgical AF ablation
techniques. The original procedure has been modiﬁed
several times to improve the results and to simplify the
surgery up to the Cox-MAZE IV modiﬁcation [6]. As the original
cut-and-sew technique for creating lesions was technically
demanding procedure with a negligible risk of bleeding
complications, a new ablation tools have been marketed to
faciliate the ablation. A variety of energies and ablation
devices have been tested and used, some of them were already
abandoned (microwave, high-intensity focused ultrasound,
laser). Based on very good efﬁcacy and safety results, the
concomitant surgical ablation of AF is nowadays recom-
mended in all AF patient who undergo a cardiac surgery for
some other primary diagnosis [4].
Since the open heart MAZE surgery is considered in most
centers to be too invasive for patients with a stand-alone form
of AF, a minimally invasive, off-pump modiﬁcations have
been developed. An early review of mid-term results of those
methods was published by Mack in 2009. An overall freedom
from AF off of antiarhythmic drugs (AADs) after 6–12 months
was 65% (57–87%) with better results for paroxysmal AF [7].
Most lately, a hybrid approach for treatment of stand-aloneAF was introduced, combining an epicardial minimally
invasive surgery with a following percutaneous catheter
ablation [8]. This approach uses a both-sides advantageous
cooperation of cardiac surgeons and cardiologists and also
shows an irreplaceable role of electrophysiologists in AF
treatment.
In this article, we describe our experiences with a minimally
invasive, surgical treatment of stand-alone AF, as well as the
evolution of methods, used energies and catheters, strategy of
indications and brieﬂy also a summary of our results.
Material and methods
Overlook
Program of the thoracoscopic AF ablation in Cardiocenter
Kralovske Vinohrady has two separate phases. Pilot group of
patients was operated between 2006 and 2010 with older
microwave (MW) and monopolar radiofrequency (RF) ablation
devices. Based on these results, we focused on patiens with
non-paroxysmal AF later and since 2013 we started operating
those patients with a bipolar RF device. More lately in 2013,
we have switched our program to a double-staged hybrid
procedure in cooperation with the department of arrhythmol-
ogy of our Cardiocenter. The program has been supported by
Charles University Cardiovascular Research Programme
PRVOUK P35.
Patient selection, evolution of indications
In our pilot group, patients with all types of stand-alone AF,
who were symptomatic and resistent to AADs, were indicated.
All of them underwent a complex cardiological examination,
including coronary angiography, echocardiography and
spirometry. Patients without indications to cardiac (mainly
coronary artery or valve) surgery were in general candidates
for the procedure. All of them signed an informed consent with
the pilot program. Protocol of the project was created in
accordance with the Declaration of Helsinki and was approved
by local ethics committee.
In 2013, we decided to start a hybrid program for patients
with persistent and long-standing persistent AF. Indications
are similar to the early group: absence of indication to other
cardiac surgery, symptomatic patients and at least one of the
AADs failed.
An absolute contraindication for all patients are pericar-
dial adhesions (e.g. history of intrapericardial surgery). The
commonly known risk factors of ablation failure (size of left
atrium, age, duration of AF, etc.) are not considered contra-
indications in general and are assessed individually, as
well as other risk factors, such as obesity or pulmonary
diseases.
Surgical procedure, evolution of methods and used devices
The goal of the procedure remains the same from the very
beginning: electrical isolation of pulmonary veins and
posterior left atrium wall by creating a continuous circum-
ferential ablation line around all four PVs (‘‘box-lesion’’) using
Fig. 2 – Ablation using a COBRA Fusion device. Catheter is
stabilized in position by suction and slightly held also with
a thoracoscopic instrument.
Fig. 3 – Right thoracoscopic look at a visible part of
‘‘box-lesion’’ on the left atrial wall, close to the interatrial
septum.
Fig. 1 – Ablation using a FLEX 10 microwave catheter.
Catheter must be held in position with a thoracoscopic
forceps.
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surgery has been described previously in our publication of
ﬁrst results and also by Dr. La Meir [9,10]. In brief, in general
anesthesia and with selective left lung ventilation, the right
thorax is entered by three working ports, a rigid videothor-
acoscopic camera with a direct optics is used. Pericardium
is widely opened anterior to a phrenic nerve and transverse
and oblique sinuses are dissected.
An insertion of the ablation catheter was a tricky part of the
surgery with the ﬁrst MW catheter, while no special introducer
was provided and the big and clumsy ﬂexible triangular
endoscopic liver retractor was used. Later RF devices were
equipped with a special ﬂexible introducers, lately also with a
magnetic tip and the positioning of the catheter around PVs
became much safer and easier. Pericardial fat is bluntly
dissected in visible areas and the correct position of catheter is
checked also by transesophageal echocardiography before the
ablation.
Three different ablation systems have been used since
2006. First, the Flex 10 (Guidant, Santa Clara, CA, USA) MW
catheter with the power setting at 65 W and two segmental
ablation of 120 and 90 s each, while the catheter had to be
pushed ﬁrmly toward the atrial wall to ensure as good contact
with the tissue as possible (Fig. 1). Second, the COBRA Adhere
XLTM (Estech, San Ramon, CA, USA) monopolar RF with
suction technology to pull the tissue toward the catheter
and with internal cooling technology to overcome the heat
sink effect while preventing the formation of coagulum at
the tissue surface. The ablation was performed in three
sequences and in two cycles of 120 s each. Third and currently
used, the COBRA FusionTM 150 (Estech) ablation system with
the use of temperature controlled, both monopolar and
bipolar RF energy, and with a suction design that eliminates
the heat sink effect (Fig. 2). We use a setting of 70 8C and
perform two cycles of 60 s each.In all systems, a circumferential movement of the catheter
was done between the ablation cycles to close the box lesion.
The lesion was checked visually and another ablation was
performed on the septum, if it did not look continuous (Fig. 3).
If patients were not in SR after ablation, a direct current
cardioversion was performed. Then, an exit block was tested
by pacing right atrium and right pulmonary veins. If not
present, additional ablation was performed. One drain was
inserted and the chest was closed. Patients were usually
extubated within a couple of hours in the intensive care unit.
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All patients received postoperatively AADs (amiodarone as
the ﬁrst choice) and anticoagulation (warfarin with target
INR of 2–3 or NOAC). They were prospectively followed for at
least one year with repeated ECG and holter monitorings
every 3 months and also an echocardiography during ﬁrst
year. Key rhythm evaluation method was in the pilot group
two 48-h holter monitorings within two weeks, after 6
months from surgery. In the hybrid ablation patients, we
switched to one-week holters after 6 and 12 months from
surgery.
The AADs were withdrawn in the pilot group after 3 months
if patients were in stable SR and warfarin after another 3 months
without AF recurrence. In hybrid patients we withdraw AADs
after 1 month from surgery so the CA is done without their
inﬂuence. We are more conservative now with the cessation of
anticoagulation. One year of stable SR without any arrhythmia
recurrence is required and the antithrombotics are then
managed according to patient's CHA2DS2-VASc score.
Results
Pilot group (MW + monopolar RF)
In the pilot group, we have operated 38 patients out of which
2/3 were men. Sixteen patients had paroxysmal and 22 had
non-paroxysmal AF. The group was very heterogenous in age
(between 42 and 75 years), duration of preoperative AF (3–240
months), ejection fraction (25–65%) and left atrial diameter
(31–52 mm). In all of them at least one AAD failed, 50% patients
had a history of electric cardioversion and 8% of catheter
ablation.
All surgeries were completed as planned except for one,
in which we had to convert on sternotomy because of
bleeding from right upper pulmonary vein. It was acciden-
tally torn with a tip of endoscopic forceps while pushing
the MW probe toward the atrial wall during the ablation. We
had zero operative and early mortality and zero incidence
of stroke. One patient had a right-sided pneumothorax,
one had a postpericardiotomy syndrome with a pericardial
and pleural effusion that was resolved with medication and
one had a temporary right phrenical nerve paresis with a
spontaneous recovery after 3 months. One patient had
an early pacemaker implantation because of postoperative
junctional rhythm.
The MW ablation system was used in 26 patients with a
mean operation time of 158 min. Percentage of patients who
remained in stable in SR was 62.5% after 3 months, 58.3% after
6 months, 58.3% after 1 year and 50% after 3 years. Four of the
SR patients underwent postoperatively an additional catheter
ablation because of AF or atrial ﬂutter recurrence, they were
included in the statistics as those with SR. Forty-two percent of
patients with SR after 3 years had a preoperative paroxysmal
and 58% had a non-paroxysmal AF.
The monopolar RF ablation was used in 12 patients with a
shorter operation time of 130 min. Sinus rhythm was present
in 42% patients after 3, 6 and 12 months and remained 42%
after 3 years but this number includes two patients who had anadditional catheter ablation for a long-term AF recidive. Sixty
percent of patients with SR after 3 years had a preoperative
paroxysmal and 40% had a non-paroxysmal AF.
Bipolar and monopolar RF + hybrid group
Since 2013, we have operated 27 patients with the new COBRA
Fusion (Estech) ablation system. Only patients with persistent
and long-standing persistent AF were indicated. Mean preoper-
ative AF duration was 37 months (range 2–138 months), mean
age was 61 years (37–74 years), mean left atrial diameter was
48 mm (39–56 mm) and mean ejection fraction was 56%
(20–65%). We had no conversion on sternotomy, zero mortality,
one temporary phrenic nerve paresis and one early postopera-
tive stroke.
First 4 patients were operated before beginning of the
hybrid program. Of those patients, 3 (75%) remain in stable
SR without the AADs during the ﬁrst postoperative year.
From 23 patients in the hybrid program, 17 patients have
already underwent also the catheter ablation procedure. All
but one (94%) have left the hospital in SR. Currently the
mean follow-up of those patients is 202 days (36–418 days)
and 14 (82%) patients remain in stable SR without AADs and
without any arrhythmia recurrence. Two patients had a
short episode of atrial ﬂutter and remain in SR on AADs, one
patient has AF.
Discussion
Interventional treatment of stand-alone AF is a dynamically
evolving and expanding component of both cardiology and
cardiac surgery. Many different surgical mini-invasive
procedures have been presented in past ten years. The
main goal was to achieve the same great results as with the
Cox-MAZE III surgery through some less invasive way. Some
centers perform the full Cox-MAZE III or IV procedure also
for patients with stand-alone AF, on one hand through a
minimally invasive surgical approach (small thoracotomy),
but on the other hand with usage of cardiopulmonary
bypass (CPB) and cardioplegic arrest. Their results are
exceptional [11], but for us, the truly mini-invasive ablation
procedure must be done on a beating heart, without usage of
the CPB.
Different surgical approaches were presented, including
unilateral and bilateral, thoracoscopic or through thoracotomy
and also a laparoscopic trans-diaphragmatic [12]. Also various
epicardial ablation catheters have been marketed with usage
of different energy sources to create lesions. The catheters
included mainly linear probes to create long continual lesions,
clamps to isolate pulmonary veins and linear pens to create
smaller lesions or to be used in hardly accessible places.
Isolation of pulmonary veins is the cornerstone of majority of
surgical and catheter AF ablation procedures. Isolation
of whole posterior left atrial wall might have even better
results than isolation of pulmonary veins alone. More
complicated lesion sets can also be achieved, but usually for
the price of increased invasivity.
In the beginning of our project in Cardiocenter Kralovske
Vinohrady, we have decided to create the box-lesion through
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 3 3 – e 1 3 8 e137as minimal approach as possible. The only device on the
market was, at that time, the Flex 10 MW catheter. We used it
in our ﬁrst series of patients with a very low complication level
and with a one-year success in almost 60% of patients.
However, the insertion of the catheter around the pulmonary
veins was complicated and the contact with the atrial tissue
was uncertain, especially in the areas with the pericardial fat.
Also the long duration of the ablation was another shortcom-
ing of this device. Later we have switched to a monopolar RF
device, where the contact was more certain as it was stabilized
by suction. The mean operation time was almost 30 min
shorter than with the Flex 10. The one-year results of only 42%
patients in SR and mainly a considerable incidence of late AF
recurrences in both MW and monopolar RF patients had forced
us to stop the program for almost two years and to revise our
strategy. Similar results can be found in literature. Pruitt has
published a long term follow-up of large series of 100 patients
operated with the Flex 10 device. After almost 2 years, only 42%
of patients remained in SR [13].
Introduction of a new bipolar/monopolar RF COBRA Fusion
catheter was a big stimulus for us. We could remain the
same minimally invasive, but with a much greater chance of
gaining a complete transmular box-lesion, as the device has
been greatly evaluated in animal off-pump models [14]. First
surgeries went smoothly and together with very promising
results of the ﬁrst patients it helped us to convince our
electrophysiologist to cooperate with us more closely. This
lead to a start of the two-staged hybrid program. We feel tense
and excited about the ﬁrst results of the hybrid procedure,
as the arrhythmia-free survival rate outreach 82% after more
than 6 months of follow-up. Those results are similar with
the review published by Gelsomino, who summarized the ﬁrst
outcomes of hybrid procedures. The success rate after one
year ranged from 85.7% to 92% in papers employing bipolar
RF [8].
Conclusions
Thoracoscopic surgical ablation presents a safe and truly mini-
invasive way of stand-alone AF treatment. Creation of box-
lesion is well feasible and its results are based on a reliability of
used ablation devices and on a selection of patients. The
results can be improved by a close cooperation with electro-
physiologists.
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